Sexually Transmitted Diseases

Skip Navigation LinksHome > October 2012 - Volume 39 - Issue 10 > Retrospective Analysis of Antimicrobial Susceptibility Trend...
Sexually Transmitted Diseases:
doi: 10.1097/OLQ.0b013e3182631c9f
Original Study

Retrospective Analysis of Antimicrobial Susceptibility Trends (2000–2009) in Neisseria gonorrhoeae Isolates from Countries in Latin America and the Caribbean Shows Evolving Resistance to Ciprofloxacin, Azithromycin and Decreased Susceptibility to Ceftriaxone

Starnino, Stefania PhD*†; GASP-LAC Working Group; Galarza, Patricia MSc, MPH§; Carvallo, María Elena Trigoso BSc; Benzaken, Adele Schwartz MD, PhD; Ballesteros, Aurora Maldonado RT, BSc**; Cruz, Olga Marina Sanabria BSc††; Hernandez, Alina Llop MD, PhD‡‡; Carbajal, José Luis Portilla MSc§§; Borthagaray, Graciela Dr. Q.F.¶¶; Payares, Daisy BSc∥∥; Dillon, Jo-Anne R. PhD*†

Erratum

Erratum

The article that appears on page 813 of the October 2012 issue of the journal has a correction in Table 3 for the Antibiotic and Dose Recommended in Peru. Ciprofloxacin DOSE 500 mg (s. d.) and; as alternatives azithromycin 1 g (s. d.) coupled with ciprofloxacin 500 mg (s. d.) or ceftriaxone 125 mg (s. d.).

Sexually Transmitted Diseases. 41(9):571, September 2014.

Collapse Box

Abstract

Background: The emergence of resistance and treatment failures to third generation cephalosporins prompted the revitalization of the global Gonococcal Antimicrobial Surveillance Program (GASP) to ensure that information regarding trends of the antimicrobial susceptibility of Neisseria gonorrhoeae isolates is up-to-date. Accordingly, former and potential GASP participants in Latin America and the Caribbean were contacted to reinitiate the GASP network in the region and to undertake a retrospective analysis of the antimicrobial susceptibility of N. gonorrhoeae isolates between 2000 and 2009.

Methods: Eleven countries participated in this retrospective analysis reporting on the susceptibility of N. gonorrhoeae isolates to up to 6 antibiotics as well as national treatment guidelines over the period. Antimicrobial susceptibility determination was carried out using combination of agar dilution and disk diffusion (Clinical Laboratory and Standards Institute) or Etest. Antimicrobial susceptibility data from each country were aggregated and analyzed for antimicrobial resistance trends in the region.

Results: More than 11,400 N. gonorrhoeae isolates were tested for antimicrobial susceptibility: 6 countries tested N. gonorrhoeae over the entire period and 5 countries tested sporadically. Decreased susceptibility to ceftriaxone was reported from 1 country (7 isolates, MICs >0.25 μg/ml) in 2007. No resistance to spectinomycin was reported. From 2000 to 2009, aggregated ciprofloxacin resistance increased from 2% (19/784) to 31% (311/1015) in 9 countries and azithromycin resistance increased from 6% (39/646) to 23% (225/962) in 4/6 reporting countries. Overall, resistance to penicillin and tetracycline decreased from 35% (441/1241) to 26% (258/975) and from 60% (476/792) to 35% (323/931), respectively.

In 2009, resistance to gentamicin (3%, 4/122), chloramphenicol (5%, 6/120), and ofloxacin (2%, 6/120) was reported from 1 country.

Conclusions: The report of ceftriaxone-resistant isolates coupled with the emergence and spread of resistance to ciprofloxacin and azithromycin in Latin America and the Caribbean in the 2000s indicates the importance of active surveillance of N. gonorrhoeae antimicrobial susceptibility to determine antimicrobial resistance emerging trends so as to promptly inform and guide the development of effective treatment options for gonococcal infections.

© Copyright 2012 American Sexually Transmitted Diseases Association

Login

Article Tools

Share

Article Level Metrics